Medifast Future Growth
Future criteria checks 0/6
Medifast's revenue and earnings are forecast to decline at 19.5% and 73.4% per annum respectively while EPS is expected to decline by 73.7% per annum.
Key information
-73.4%
Earnings growth rate
-73.7%
EPS growth rate
| Personal Products earnings growth | 25.3% |
| Revenue growth rate | -19.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 29 Oct 2024 |
Recent future growth updates
Recent updates
Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation
Sep 03Medifast Business Continues To Shrink, Stock Still Risky
Aug 27Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing
Jun 26Medifast: Significant Undervaluation Even As Struggles Persist
May 24At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
May 24
Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop
May 24Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings
May 06The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence
May 01Medifast: Cheap Valuation, Uncertain Future
Mar 20Medifast Is Getting Attractive
Mar 07Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings
Feb 22Medifast Share Price Loses Weight, But Is There Still Value To Be Had?
Jan 20Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?
Dec 09Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome
Nov 24Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?
Nov 21Medifast: Unveiling A Challenge Beyond Weight Loss Drugs
Nov 09Medifast: The Race To Weight-Loss Drugs Not Lost Yet
Oct 09Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs
Aug 04Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?
Jul 26In The Murky MLM Space, Medifast Might Actually Hold Some Promise
Jul 21Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Jul 05Medifast: In Survival Mode Against Diet Pills And The Recession
Jun 14Medifast Holds Value During Headwinds
May 28Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M
Feb 21Medifast: A Low Earnings Multiple Despite Strong Financial Performance
Feb 07At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
Jan 19Medifast declares $1.64 dividend
Dec 08A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Dec 01Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Nov 10One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates
Nov 08Medifast: This High-Yield Blue Chip Dividend Stock Is A Strong Buy
Nov 06What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?
Oct 20We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt
Sep 18Medifast declares $1.64 dividend
Sep 08Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?
Sep 02Medifast: Let's Dive Into Its Q2 Earnings And Assess The Bad And The Good
Aug 21Medifast, Inc. (NYSE:MED) Analysts Are Reducing Their Forecasts For This Year
Aug 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 562 | 9 | 25 | 30 | 2 |
| 12/31/2024 | 613 | -3 | 23 | 32 | 2 |
| 6/30/2024 | 770 | 29 | 54 | 61 | N/A |
| 3/31/2024 | 898 | 68 | 85 | 91 | N/A |
| 12/31/2023 | 1,072 | 99 | 141 | 148 | N/A |
| 9/30/2023 | 1,218 | 120 | 174 | 189 | N/A |
| 6/30/2023 | 1,373 | 133 | 200 | 214 | N/A |
| 3/31/2023 | 1,530 | 142 | 199 | 215 | N/A |
| 12/31/2022 | 1,599 | 144 | 178 | 195 | N/A |
| 9/30/2022 | 1,639 | 151 | 116 | 135 | N/A |
| 6/30/2022 | 1,662 | 157 | 68 | 96 | N/A |
| 3/31/2022 | 1,603 | 165 | 40 | 73 | N/A |
| 12/31/2021 | 1,526 | 164 | 60 | 95 | N/A |
| 9/30/2021 | 1,413 | 158 | 97 | 122 | N/A |
| 6/30/2021 | 1,271 | 150 | 130 | 147 | N/A |
| 3/31/2021 | 1,097 | 125 | 174 | 184 | N/A |
| 12/31/2020 | 935 | 103 | 139 | 145 | N/A |
| 9/30/2020 | 841 | 95 | 140 | 145 | N/A |
| 6/30/2020 | 759 | 76 | 118 | 121 | N/A |
| 3/31/2020 | 726 | 76 | 72 | 78 | N/A |
| 12/31/2019 | 714 | 78 | 74 | 84 | N/A |
| 9/30/2019 | 689 | 74 | 70 | 80 | N/A |
| 6/30/2019 | 638 | 72 | 60 | 69 | N/A |
| 3/31/2019 | 568 | 64 | 67 | 76 | N/A |
| 12/31/2018 | 501 | 56 | 56 | 61 | N/A |
| 9/30/2018 | 433 | 47 | 51 | 55 | N/A |
| 6/30/2018 | 371 | 40 | 57 | 61 | N/A |
| 3/31/2018 | 330 | 34 | N/A | 55 | N/A |
| 12/31/2017 | 302 | 28 | N/A | 43 | N/A |
| 9/30/2017 | 286 | 25 | N/A | 33 | N/A |
| 6/30/2017 | 277 | 24 | N/A | 27 | N/A |
| 3/31/2017 | 273 | 20 | N/A | 24 | N/A |
| 12/31/2016 | 275 | 18 | N/A | 25 | N/A |
| 9/30/2016 | 273 | 18 | N/A | 28 | N/A |
| 6/30/2016 | 271 | 17 | N/A | 30 | N/A |
| 3/31/2016 | 272 | 19 | N/A | 27 | N/A |
| 12/31/2015 | 273 | 20 | N/A | 29 | N/A |
| 9/30/2015 | 274 | 18 | N/A | 28 | N/A |
| 6/30/2015 | 277 | 18 | N/A | 27 | N/A |
| 3/31/2015 | 279 | 19 | N/A | 25 | N/A |
| 12/31/2014 | 285 | 21 | N/A | 26 | N/A |
| 9/30/2014 | 267 | 27 | N/A | 33 | N/A |
| 6/30/2014 | 285 | 27 | N/A | 31 | N/A |
| 3/31/2014 | 307 | 28 | N/A | 38 | N/A |
| 12/31/2013 | 324 | 27 | N/A | 42 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MED's earnings are forecast to decline over the next 3 years (-73.4% per year).
Earnings vs Market: MED's earnings are forecast to decline over the next 3 years (-73.4% per year).
High Growth Earnings: MED's earnings are forecast to decline over the next 3 years.
Revenue vs Market: MED's revenue is expected to decline over the next 3 years (-19.5% per year).
High Growth Revenue: MED's revenue is forecast to decline over the next 3 years (-19.5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MED's Return on Equity is forecast to be high in 3 years time